Overview

Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study

Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The investigators will conduct tau positron emission tomography (PET) scans on 125 adults using the radiopharmaceutical Flortaucipir F18 ([18F]AV-1451). This will allow the investigators to determine tau deposition across adults of different ages and assess the relationship of current tau burden to cognitive function and amyloid deposition collected over the previous 10-year interval.
Phase:
Phase 2
Details
Lead Sponsor:
Neil M Rofsky, MD, MHA